Celiac Disease in the Hospitalized Patient: Diagnosis, Complications, and the Future Beyond Gluten-Free Diets

Mixed Connective Tissue Disease in the Hospitalized Patient: Anti-U1 RNP, Overlap Syndromes, and the Lungs That Kill

In this episode of Hospital Medicine Unplugged, we unpack mixed connective tissue disease—recognize the overlap syndrome hiding between lupus, scleroderma, and myositis, and aggressively monitor the pulmonary complications that drive morbidity and mortality. MCTD is defined by high-titer anti-U1 RNP antibodies plus overlapping connective tissue disease features. The hallmark clues: • Raynaud phenomenon • Swollen hands • Sclerodactyly • Inflammatory arthritis • Myositis • GERD and esophageal dysmotility Raynaud’s is often the earliest manifestation, and scleroderma-type findings help distinguish MCTD from lupus in anti-RNP–positive patients. The major threat is pulmonary disease: • Interstitial lung disease (ILD) • Pulmonary arterial hypertension (PAH) PAH remains the leading cause of death, making routine pulmonary surveillance essential: • Pulmonary function tests with DLCO • High-resolution CT when indicated • Echocardiography for PAH screening Treatment depends on organ involvement: • Steroids for inflammatory flares • Mycophenolate, methotrexate, or cyclophosphamide for ILD and systemic disease • Rituximab for refractory cases For MCTD-associated PAH: • Endothelin receptor antagonists • PDE-5 inhibitors • Prostacyclin pathway therapy • Immunosuppression may help more than in systemic sclerosis–associated PAH. Key pearl: many patients achieve remission or stable disease, but up to one-quarter eventually evolve into a more defined connective tissue disease—most commonly systemic sclerosis or lupus. We close with the system moves: don’t dismiss Raynaud’s plus swollen hands as “nonspecific,” screen aggressively for ILD and PAH, trend pulmonary function over time, and recognize that lung complications—not arthritis—determine long-term outcomes in MCTD. The antibody may define the diagnosis, but the lungs define the prognosis.

Myelodysplastic Syndromes in the Hospitalized Patient: Clonal Cytopenias, Risk Stratification, and When to Transplant

In this episode of Hospital Medicine Unplugged, we break down myelodysplastic syndromes—recognize the unexplained cytopenias, understand the modern molecular classification, and risk-stratify patients before progression to AML. The WHO 2022 classification shifted MDS from a purely morphologic disease to a genetically informed diagnosis. New entities include MDS with SF3B1 mutation, isolated del(5q), and biallelic TP53-mutated MDS, one of the highest-risk subtypes. Blast categories are now simplified into low blasts, increased blasts-1 (5–9%), and increased blasts-2 (10–19%). Diagnosis requires: • Persistent cytopenias • Dysplasia in >10% of a marrow lineage or defining cytogenetic abnormalities • Exclusion of alternative causes Bone marrow biopsy remains essential, and unexplained cytopenias with clonal mutations that don’t meet MDS criteria are now classified as CCUS. Risk stratification centers on the IPSS-R, incorporating: • Cytogenetics • Blast percentage • Hemoglobin • Platelets • Neutrophil count Lower-risk disease focuses on symptom control and transfusion reduction. Higher-risk disease focuses on delaying AML transformation and improving survival. For anemia in lower-risk MDS: • ESAs remain common first-line therapy • Luspatercept is especially effective in SF3B1-mutated or ring sideroblast disease and outperformed epoetin alfa in recent trials. For higher-risk disease: • Azacitidine is standard frontline therapy and improves overall survival • Decitabine is an alternative • Oral decitabine-cedazuridine allows outpatient treatment Key pearl: responses to hypomethylating agents are delayed—patients often need at least 4–6 cycles before declaring failure. The only curative therapy is allogeneic stem cell transplantation: • Consider for higher-risk disease and select lower-risk patients with severe cytopenias or poor-risk mutations • Reduced-intensity conditioning expanded transplant eligibility into older adults • TP53-mutated disease remains particularly challenging, even after transplant We close with the system moves: investigate unexplained macrocytic anemia and cytopenias early, integrate molecular testing into diagnosis and prognosis, avoid prematurely stopping hypomethylating therapy, and refer transplant-eligible patients before progression to AML. Not every pancytopenia is “just aging marrow”—sometimes it’s a clonal stem-cell disorder announcing itself before leukemia arrives.

Cardiac Amyloidosis in the Hospitalized Patient: The HFpEF Diagnosis You’re Missing

In this episode of Hospital Medicine Unplugged, we unpack cardiac amyloidosis—recognize the red flags hiding inside “routine HFpEF,” diagnose ATTR noninvasively, and start disease-modifying therapy before restrictive physiology becomes irreversible. ATTR cardiac amyloidosis is far more common than previously recognized, especially in older adults with HFpEF and increased LV wall thickness. Key clues include voltage-mass discordance—thick ventricles on echo with surprisingly low ECG voltage—and extracardiac findings like carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, or biceps tendon rupture that may precede diagnosis by years. Echo pearls: • Increased wall thickness with preserved EF • Restrictive filling pattern • Biatrial enlargement • Classic “apical sparing” strain pattern The modern diagnostic breakthrough is nuclear imaging: • Grade 2–3 uptake on technetium-PYP scan + negative monoclonal protein testing = essentially diagnostic for ATTR-CM without biopsy. Never skip monoclonal protein screening: • Serum free light chains • Serum immunofixation • Urine immunofixation This distinction matters because AL amyloidosis is a hematologic emergency requiring plasma-cell–directed therapy. Treatment changed dramatically with tafamidis: • Reduces mortality • Lowers cardiovascular hospitalizations • Works best when started early Acoramidis joined the field in 2024 as another TTR stabilizer with similar benefits. Heart failure management is different here: • Loop diuretics are the backbone • ACE inhibitors, ARBs, and beta-blockers are often poorly tolerated • Avoid digoxin and non-dihydropyridine calcium channel blockers Key pearl: anticoagulate atrial fibrillation regardless of CHA₂DS₂-VASc score due to extreme thromboembolic risk. We close with the system moves: when HFpEF doesn’t quite fit—especially with unexplained LVH, neuropathy, orthopedic history, or voltage-mass discordance—think amyloid early, order monoclonal protein studies plus PYP scanning, and start disease-modifying therapy before fibrosis and restrictive failure dominate the trajectory. Not all HFpEF is hypertensive heart disease—sometimes the diagnosis is hiding in the carpal tunnel scar.

Sarcoidosis in the Hospitalized Patient: Multisystem Granulomas and the Organs You Can’t Miss

In this episode of Hospital Medicine Unplugged, we tackle sarcoidosis—recognize the classic presentations, screen aggressively for silent organ involvement, and treat the patients at highest risk for irreversible damage or sudden death. Diagnosis requires three things: compatible clinical presentation, non-caseating granulomas, and exclusion of alternative granulomatous disease like TB, fungal infection, or malignancy. Some syndromes are classic enough to skip biopsy, including Löfgren syndrome (bilateral hilar adenopathy, erythema nodosum, arthritis, fever) and lupus pernio. Most hospitalized patients, though, need tissue confirmation—typically via EBUS-guided transbronchial needle aspiration for intrathoracic lymphadenopathy. Once diagnosed, the mission shifts to multisystem screening: • Pulmonary: chest imaging + PFTs with DLCO • Cardiac: ECG for all patients; cardiac MRI or FDG PET for symptoms, arrhythmias, or conduction disease • Ophthalmologic: slit-lamp examination • Labs: CBC, creatinine, calcium, alkaline phosphatase, vitamin D metabolites when indicated Cardiac sarcoidosis is a major killer and can present with AV block, ventricular arrhythmias, syncope, or unexplained cardiomyopathy. Neurosarcoidosis can cause cranial neuropathies, meningitis, seizures, or spinal cord disease—both require aggressive recognition and treatment. Not all sarcoidosis needs therapy. Treat when there’s risk of organ damage, death, or severe symptoms: • Cardiac sarcoidosis • Neurosarcoidosis • Progressive pulmonary disease • Ocular disease • Symptomatic hypercalcemia Treatment backbone: • Prednisone 20–40 mg/day for most disease • Higher-dose steroids for cardiac/neuro involvement • IV methylprednisolone for life-threatening presentations Steroid-sparing therapy matters early: • Methotrexate is the preferred second-line agent • Azathioprine, mycophenolate, and leflunomide are alternatives • Infliximab or other biologics for refractory disease Cardiac sarcoidosis often needs more than immunosuppression: • ICDs for ventricular arrhythmia risk • Pacemakers for conduction disease • Catheter ablation for refractory VT Key inpatient pearls: • Monitor calcium and steroid toxicity • Use telemetry if cardiac involvement suspected • Watch for progressive hypoxemia or arrhythmias • Involve pulmonology, cardiology, ophthalmology, and neurology early We close with the system moves: build a standardized sarcoidosis screening pathway, default to ECG + pulmonary testing + ophthalmology evaluation at diagnosis, escalate rapidly to cardiac imaging when red flags appear, and initiate steroid-sparing therapy early for chronic disease. Granulomas are only the start—screen every organ, respect cardiac sarcoidosis, and treat before inflammation becomes permanent fibrosis.

Autoimmune Encephalitis in a Hospitalized Patient: Diagnose Early, Treat Fast, Recover Long

In this episode of Hospital Medicine Unplugged, we unpack autoimmune encephalitis—recognize the red flags early, treat aggressively before antibody results return, and support the long recovery arc that often extends years beyond discharge. We open with the bedside reality: autoimmune encephalitis is frequently missed because it masquerades as psychiatry, infection, toxic-metabolic disease, or unexplained delirium. The key clue is rapid progression over days to weeks with combinations of psychiatric symptoms, memory loss, seizures, dyskinesias, autonomic instability, speech dysfunction, or decreased consciousness. Diagnosis starts clinically—not with waiting for antibodies. The Graus 2016 framework emphasizes a tiered approach using history, exam, MRI, EEG, CSF, and syndrome recognition. For anti-NMDA receptor encephalitis, probable diagnosis requires rapid onset (<3 months) of at least four major symptom groups (psychiatric/cognitive dysfunction, speech dysfunction, seizures, movement disorder, decreased consciousness, autonomic dysfunction) plus abnormal EEG or CSF findings—or three symptom groups with a teratoma identified. Normal MRI does not exclude disease. Core diagnostic workup: • MRI brain with and without contrast • EEG (often diffuse slowing or extreme delta brush in anti-NMDAR disease) • Lumbar puncture with CSF cell count, protein, oligoclonal bands, infectious PCRs, autoimmune panels • Serum + CSF neuronal antibody testing • Broad infectious exclusion—especially HSV encephalitis • Tumor screening (ovarian teratoma, thymoma, small-cell lung cancer, etc.) The critical management principle: do not delay immunotherapy waiting for antibodies. Seronegative autoimmune encephalitis exists, testing sensitivity is imperfect, and treatment delay worsens outcomes. First-line therapy builds the immunotherapy backbone: • High-dose corticosteroids • IVIG • Plasma exchange (PLEX) Evidence increasingly favors combination therapy over isolated treatment. Meta-analysis data from >1,500 patients showed therapeutic apheresis alone or combination regimens (steroids + IVIG or all three modalities) had the best odds of favorable recovery. Failure to initiate immunotherapy within 30 days was associated with markedly worse outcomes. If first-line treatment stalls: • Rituximab becomes the preferred second-line agent • Cyclophosphamide remains an option in refractory disease • Escalation should happen early in severe or persistent cases rather than waiting months Rituximab deserves special attention—it not only improves refractory disease but also substantially lowers relapse risk, with studies demonstrating nearly a six-fold reduction in recurrence odds. ICU pearls you don’t want to miss: • Autonomic instability can become life-threatening • Refractory seizures and status epilepticus are common • Dyskinesias may require deep sedation • Ventilator dependence is frequent in severe anti-NMDAR disease • Always continue aggressive rehabilitation planning early Tumor search is not optional: • Ovarian teratoma in young women with anti-NMDAR encephalitis • Thymoma in LGI1/CASPR2 syndromes • Small-cell lung cancer in classic paraneoplastic syndromes When present, tumor removal is treatment and significantly affects relapse risk and neurologic recovery. Recovery is where expectations need recalibration. Improvement is often slow, nonlinear, and incomplete despite “good” functional scores. About 75–81% of anti-NMDAR patients eventually achieve substantial recovery, but progress may continue for 24–36 months. The largest gains occur in the first 6 months, yet persistent deficits in memory, language, fatigue, emotional health, and social functioning are extremely common. One of the most important recent observations: autoimmune encephalitis patients continue improving well beyond the timeline expected for infectious encephalitis. Critically ill autoimmune cases may show functional gains throughout the entire first year, reinforcing the importance of prolonged rehab and longitudinal neurologic support. Relapse prevention matters: • Relapse occurs in roughly 12–25% • Risk rises when tumors are not removed or second-line immunotherapy is omitted • Rituximab is increasingly used as relapse-prevention therapy in high-risk patients Pediatric disease brings additional nuance: • Behavioral and psychiatric presentations dominate early • Earlier immune treatment correlates with better outcomes • Cognitive recovery trajectories differ from adults and may evolve over years We close with the system moves: (1) build an encephalitis pathway that triggers simultaneous infectious + autoimmune evaluation; (2) default to early EEG, CSF, MRI, and antibody panels; (3) begin empiric immunotherapy when suspicion is high; (4) create automatic malignancy-screening pathways; (5) escalate rapidly to rituximab when first-line response is incomplete; (6) embed rehab, neuropsychology, psychiatry, and family support early; (7) follow patients longitudinally because recovery continues long after discharge. Fast recognition, early immunotherapy, aggressive escalation, and long-term rehabilitation—autoimmune encephalitis is treatable, but only if you think about it before the antibodies come back.